Genesis Backed Startups Closer to Market
New capital investments involving existing investors will bring two health care startups backed by Genesis Innovation Group closer to the market.
News
Embody, Inc. Announces $9.3 M Series A Funding Round
Embody, Inc., a privately-held medical device company focused on soft tissue repair, announced that it has closed a $9.3 million Series A funding round with participation from cultivate(MD).
Embody Receives $2.5 Million Phase II Research Award
Embody, a cultivate(MD) portfolio company, is receiving a $2.5 million Phase II Small Business Innovation Research award through the Defense Advanced Research Projects Agency (DARPA).
Genesis Innovation Group’s cultivate(MD)™ Seed Fund Announces Participation in Virtual Incision’s $20 Million Financing to Advance First-of-its-Kind Mini-Robot for General Surgery Abdominal Procedures
HOLLAND, Mich., Jan. 13, 2020 /PRNewswire/ — Genesis Innovation Group’s cultivate(MD) Seed Fund, a fund focused on investments into early-stage healthcare companies with innovative technologies, announces its participation in Virtual …
Virtual Incision Announces $20 Million Financing
Virtual Incision, a cultivate(MD) portfolio company, announced today that it has closed announced it has raised $20 million in a Series B+ financing.
Medical Startup Receives FDA Clearance
A medical device startup in the region has received FDA clearance for a new product.
2020 ASAP Meeting
Genesis is proud to be a sponsor of the 2020 ASAP Meeting (Advanced Shoulder ArthroPlasty). This year’s meeting will be held on January 16-18, 2020 in Snowbird, UT.
Shoulder Innovations Announces FDA 510(K) Clearance For Inset Plus™ Augmented Glenoids For Total Shoulder System
HOLLAND, Mich., December 10th, 2019 — Shoulder Innovations, (SI), a leading innovator in the development of shoulder replacement systems, announced today that they have received FDA clearance for their InSet …
Ward Detwiler Named To Crain’s Top 40 Under 40
Congratulations to Ward Detwiler, who was just awarded as a Crain’s Top 40 Under 40!